Antiviral Effects and Molecular Mechanisms of Marine Compounds

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Biotechnology Related to Drug Discovery or Production".

Deadline for manuscript submissions: 30 April 2024 | Viewed by 2248

Special Issue Editor

School of Medicine and Pharmacy, Ocean University of China, Qingdao, China
Interests: anti-viral pharmacology; marine drugs; virology; viral glycobiology

Special Issue Information

Dear Colleagues,                 

In recent years, the constant outbreak of emerging or reemerging viral diseases has caused serious harm to human health. Despite the success of approved antiviral drugs, drug resistance, toxicity, and cost remained unresolved issues. Hence, the development of novel antiviral agents is of high importance. Recently, the studies on the antiviral activities of marine natural products are attracting increasing attention all over the world. Marine natural products can reveal uncommon and rare structure features and pharmacological activities that are not found in the terrestrial environment, which is helpful to find antiviral agents with novel targets that can be used alone or in combination with existing drugs.

This Special Issue aims to provide a comprehensive and advanced publication platform for studies concerning all aspects of antiviral research of marine natural compounds. We invite academic and industry scientists to submit reviews and original research articles that highlight the antiviral activities and molecular mechanisms of known or novel marine compounds. We also welcome articles that describe the recent progress in research on marine-derived antiviral agents in clinical trials, relating to their structural features and clinical applications.

Dr. Wei Wang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marine polysaccharides
  • marine peptides
  • secondary metabolites
  • structure features
  • structure–activity relationship
  • antiviral effects
  • mechanism of action
  • molecular target
  • drug resistance

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 1406 KiB  
Communication
Isolation and Characterization of Targeting-HBsAg VNAR Single Domain Antibodies from Whitespotted Bamboo Sharks (Chiloscyllium plagiosum)
by Xierui Jiang, Shan Sun, Zengpeng Li and Mingliang Chen
Mar. Drugs 2023, 21(4), 237; https://doi.org/10.3390/md21040237 - 12 Apr 2023
Cited by 1 | Viewed by 1683
Abstract
Immunoglobulin new antigen receptor (IgNAR) is a naturally occurring antibody that consists of only two heavy chains with two independent variable domains. The variable binding domain of IgNAR, called variable new antigen receptor (VNAR), is attractive due to its solubility, thermal stability, and [...] Read more.
Immunoglobulin new antigen receptor (IgNAR) is a naturally occurring antibody that consists of only two heavy chains with two independent variable domains. The variable binding domain of IgNAR, called variable new antigen receptor (VNAR), is attractive due to its solubility, thermal stability, and small size. Hepatitis B surface antigen (HBsAg) is a viral capsid protein found on the surface of the Hepatitis B virus (HBV). It appears in the blood of an individual infected with HBV and is widely used as a diagnostic marker for HBV infection. In this study, the whitespotted bamboo sharks (Chiloscyllium plagiosum) were immunized with the recombinant HBsAg protein. Peripheral blood leukocytes (PBLs) of immunized bamboo sharks were further isolated and used to construct a VNAR-targeted HBsAg phage display library. The 20 specific VNARs against HBsAg were then isolated by bio-panning and phage ELISA. The 50% of maximal effect (EC50) of three nanobodies, including HB14, HB17, and HB18, were 4.864 nM, 4.260 nM, and 8.979 nM, respectively. The Sandwich ELISA assay further showed that these three nanobodies interacted with different epitopes of HBsAg protein. When taken together, our results provide a new possibility for the application of VNAR in HBV diagnosis and also demonstrate the feasibility of using VNAR for medical testing. Full article
(This article belongs to the Special Issue Antiviral Effects and Molecular Mechanisms of Marine Compounds)
Show Figures

Figure 1

Back to TopTop